Nectar Lifesciences Limited (LUX: NECLF)
Luxembourg
· Delayed Price · Currency is EUR · Price in USD0.414
0.00 (0.00%)
At close: Nov 19, 2024
Nectar Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 16,787 | 16,841 | 15,237 | 16,688 | 15,433 | 23,664 | Upgrade
|
| Other Revenue | -87.03 | 4.85 | 0.25 | 0.25 | 0.25 | 0.25 | Upgrade
|
| Revenue | 16,700 | 16,846 | 15,237 | 16,689 | 15,433 | 23,664 | Upgrade
|
| Revenue Growth (YoY) | 9.57% | 10.56% | -8.70% | 8.13% | -34.78% | -14.97% | Upgrade
|
| Cost of Revenue | 11,687 | 12,022 | 11,593 | 12,231 | 11,571 | 18,586 | Upgrade
|
| Gross Profit | 5,014 | 4,823 | 3,644 | 4,457 | 3,862 | 5,078 | Upgrade
|
| Selling, General & Admin | 956.25 | 865.64 | 796.01 | 763.07 | 751.49 | 828.16 | Upgrade
|
| Other Operating Expenses | 2,413 | 2,422 | 2,309 | 2,109 | 1,888 | 2,049 | Upgrade
|
| Operating Expenses | 3,980 | 3,895 | 3,696 | 3,441 | 3,362 | 3,485 | Upgrade
|
| Operating Income | 1,034 | 928.41 | -51.72 | 1,016 | 499.91 | 1,593 | Upgrade
|
| Interest Expense | -912.66 | -896.23 | -827.98 | -699.44 | -857.65 | -918.07 | Upgrade
|
| Interest & Investment Income | 123.9 | 123.9 | 17.26 | 18.84 | 26.82 | 27.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 97.5 | 97.5 | 98.78 | 4.68 | -84.92 | 64.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -72.69 | -72.69 | -65.67 | -93.34 | -177.78 | -394.48 | Upgrade
|
| EBT Excluding Unusual Items | 269.72 | 180.89 | -829.33 | 246.71 | -593.62 | 371.86 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.8 | 1.8 | 1.05 | 0.03 | 0.4 | -0.39 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 404.08 | 94.07 | -1.31 | 3.24 | Upgrade
|
| Other Unusual Items | - | - | - | - | -253.15 | - | Upgrade
|
| Pretax Income | 271.52 | 182.69 | -424.2 | 340.81 | -847.68 | 374.71 | Upgrade
|
| Income Tax Expense | 164.25 | 132.74 | -182.37 | 90.34 | -115.04 | 56.82 | Upgrade
|
| Net Income | 107.27 | 49.95 | -241.83 | 250.47 | -732.64 | 317.89 | Upgrade
|
| Net Income to Common | 107.27 | 49.95 | -241.83 | 250.47 | -732.64 | 317.89 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -33.22% | Upgrade
|
| Shares Outstanding (Basic) | 228 | 224 | 224 | 224 | 224 | 224 | Upgrade
|
| Shares Outstanding (Diluted) | 228 | 224 | 224 | 224 | 224 | 224 | Upgrade
|
| Shares Change (YoY) | 2.93% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.47 | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 | Upgrade
|
| EPS (Diluted) | 0.47 | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 | Upgrade
|
| EPS Growth | - | - | - | - | - | -33.14% | Upgrade
|
| Free Cash Flow | 1,366 | 1,953 | 1,036 | 700.35 | -98.62 | 2,302 | Upgrade
|
| Free Cash Flow Per Share | 5.99 | 8.71 | 4.62 | 3.12 | -0.44 | 10.26 | Upgrade
|
| Dividend Per Share | - | - | - | - | - | 0.050 | Upgrade
|
| Gross Margin | 30.02% | 28.63% | 23.92% | 26.71% | 25.02% | 21.46% | Upgrade
|
| Operating Margin | 6.19% | 5.51% | -0.34% | 6.09% | 3.24% | 6.73% | Upgrade
|
| Profit Margin | 0.64% | 0.30% | -1.59% | 1.50% | -4.75% | 1.34% | Upgrade
|
| Free Cash Flow Margin | 8.18% | 11.59% | 6.80% | 4.20% | -0.64% | 9.73% | Upgrade
|
| EBITDA | 1,644 | 1,536 | 539.47 | 1,586 | 1,102 | 2,201 | Upgrade
|
| EBITDA Margin | 9.85% | 9.12% | 3.54% | 9.50% | 7.14% | 9.30% | Upgrade
|
| D&A For EBITDA | 610.82 | 607.18 | 591.19 | 569.68 | 602.53 | 607.66 | Upgrade
|
| EBIT | 1,034 | 928.41 | -51.72 | 1,016 | 499.91 | 1,593 | Upgrade
|
| EBIT Margin | 6.19% | 5.51% | -0.34% | 6.09% | 3.24% | 6.73% | Upgrade
|
| Effective Tax Rate | 60.49% | 72.66% | - | 26.51% | - | 15.16% | Upgrade
|
| Revenue as Reported | 16,841 | 16,987 | 15,668 | 16,802 | 15,471 | 23,707 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.